CorMedix Inc. (NASDAQ:CRMD) defied analyst predictions to release its third-quarter results, which were ahead of market expectations. Revenues and losses per share were both better than expected, with revenues of US$11m leading estimates by 5.7%. Statutory losses were smaller than the analystsexpected, coming in at US$0.05 per share. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

Taking into account the latest results, the consensus forecast from CorMedix's four analysts is for revenues of US$110.7m in 2025. This reflects a substantial 803% improvement in revenue compared to the last 12 months. Earnings are expected to improve, with CorMedix forecast to report a statutory profit of US$0.29 per share. In the lead-up to this report, the analysts had been modelling revenues of US$99.6m and earnings per share (EPS) of US$0.18 in 2025. There has definitely been an improvement in perception after these results, with the analysts noticeably increasing both their earnings and revenue estimates.

Althoughthe analysts have upgraded their earnings estimates, there was no change to the consensus price target of US$14.25, suggesting that the forecast performance does not have a long term impact on the company's valuation. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on CorMedix, with the most bullish analyst valuing it at US$19.00 and the most bearish at US$10.00 per share. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. It's clear from the latest estimates that CorMedix's rate of growth is expected to accelerate meaningfully, with the forecast 5x annualised revenue growth to the end of 2025 noticeably faster than its historical growth of 81% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 10% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that CorMedix is expected to grow much faster than its industry.

The Bottom Line

The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around CorMedix's earnings potential next year. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for CorMedix going out to 2026, and you can see them free on our platform here.

Plus, you should also learn about the 3 warning signs we've spotted with CorMedix .

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.